SABS (SAB Biotherapeutics) OCF Margin %: 0.00% (As of Mar. 2026)


SABS SAB Biotherapeutics Inc SABS
26 GF Score
Price $3.84
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics OCF Margin %?

SAB Biotherapeutics SABS -1.03% 26 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 960 Biotechnology companies, SAB Biotherapeutics ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. SAB Biotherapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was $-14.27 Mil. SAB Biotherapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, SAB Biotherapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, SAB Biotherapeutics's current OCF Yield % is -17.45%.

The historical rank and industry rank for SAB Biotherapeutics's OCF Margin % or its related term are showing as below:


During the past 7 years, the highest OCF Margin % of SAB Biotherapeutics was -267.69%. The lowest was -267.69%. And the median was -267.69%.

SABS's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

SAB Biotherapeutics OCF Margin % Related Terms

SAB Biotherapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for SAB Biotherapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics OCF Margin % Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

SAB Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SABS
26GF Score
SAB Biotherapeutics Inc SABS
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

SAB Biotherapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-44.775/0
= %

SAB Biotherapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-14.271/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
SAB Biotherapeutics (SABS) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on SAB Biotherapeutics and its competitors. According to the industry distribution chart, SAB Biotherapeutics ranks #999999 out of 960 companies in the Biotechnology industry.
Is SAB Biotherapeutics' OCF Margin % too high?
SAB Biotherapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, SAB Biotherapeutics ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' OCF Margin % compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #999999 out of 960 companies for OCF Margin %. This places SAB Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score

Get the complete analysis for SABS

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price